SOURCE: Kantar Health

Kantar Health

June 21, 2011 10:47 ET

Kantar Health to Present Key Highlights From ASCO 2011

Kantar Health Oncology Experts and Synix Inc. to Host 7th Annual Seminar in Tokyo

NEW YORK, NY--(Marketwire - Jun 21, 2011) - Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, today announced that it will host a seminar for pharmaceutical companies highlighting key research from the 2011 American Society of Clinical Oncology (ASCO) annual meeting. The seminar is presented in conjunction with Synix Inc., Kantar Health's partner in Japan.

The seminar, "Key Highlights from ASCO 2011," will take place at Conference Square M+ in Tokyo on Thursday, July 14 from 1 to 5 pm and will be led by Kantar Health oncology specialists Gordon Gochenauer, Director, and Neesha Suvarna, Ph.D., Associate Consultant. The presentation will focus on findings involving drugs in development for the major tumor types in Japan, including:

  • Sarcoma: Is Sarcoma the Next Renal Cell Carcinoma? (pazopanib and ridaforolimus)
  • Ovarian: Is Avastin Better Suited in Later Lines? (Avastin plus carboplatin/gemcitabine and olaparib)
  • Melanoma: The Game Has Changed! (Yervoy and vemurafenib)
  • Non-Small Cell Lung Cancer: Advances in Personalized Care (crizotinib, Tarceva and cMET inhibitors)
  • Breast: Is Improving Overall Survival an Insurmountable Barrier for First-Line Trials? (iniparib)
  • Prostate: Sequencing Recent Approvals and the Implication of Circulating Tumor Cells for Future Development (Zytiga, Jevtana and Provenge)
  • Renal Cell Carcinoma: Can the Market Sustain Further Entrants? (Axitinib versus Nexavar, Votrient and tivozanib)
  • Pancreatic: Potential New Options in the Future (TS-1 in combination with gemcitabine)
  • Myeloproliferative Neoplasms: A New Standard in a Previously Recalcitrant Disease (JAK 2 inhibitors)

To register for "Key Highlights from ASCO 2011," please visit or contact Kousuke Kitamura, Synix Oncology Market Assessment, Synix Inc., at

About CancerMPact®
CancerMPact® is an invaluable oncology decision support tool for market analysis, strategic planning, and identification of commercial opportunities in the U.S., Western Europe, Japan and China. This tool is composed of web-based integrated modules: Treatment Practices and Evolution, Patient Metrics, and Monthly Drugs and Regimens. More than 30 tumor types are covered within the modules. Custom studies are available upon request.

Every year since 2005 senior members of the CancerMPact team have traveled to Tokyo to present this seminar on highlights from the ASCO meeting.

About Kantar Health (
As experts in pharmaceutical and biotechnology consulting and market research, Kantar Health offers unique insights and products that deliver proven results for marketing insights, brand marketing, business development and health economics and outcomes professionals, including:

  • The greatest breadth and depth of epidemiology information in the world, spanning patient-reported outcomes and patient care by country, therapy area, specialist -- or whatever combination of data you require
  • Unmatched experience in the complex oncology market that encompasses business development, clinical management, emerging technologies, marketing and sales, payers and providers, reimbursement and strategic and product planning
  • A unique global source of KOLs for multiple therapy areas

Kantar Health's team combines doctorate-level scientific expertise with strong business know-how, ensuring that solutions are both evidence-based and commercially focused. We offer a wide range of expertise in emerging as well as established markets, spanning the product life cycle from product portfolio management to licensing, market access to brand and reputation management, detailing to clinical research, patient outcomes and sales force effectiveness to health and safety. And as part of WPP, the largest marketing agency in the world, Kantar Health can leverage the power of the global group with shared offline and online research methodologies but remain culturally specific and nimble. Kantar Health focuses on getting you the best return.

About Synix Inc.
Synix is a Tokyo-based health care marketing consultancy company, serving over 40 pharmaceutical companies in Japan. Synix has worked with Kantar Health in Japan for over 10 years on Epi Database®, CancerMPact® and miscellaneous Commercial Development practice engagements and activities.

Contact Information

  • Contact Information
    For more information on Kantar Health, please contact
    Paula Paradise
    Vice President of Global Marketing
    Email Contact